ARCHIVES

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: DCBD Board Adds Concept Review To Duties, Rabson Seeks Four Additional Member

September 19, 1980

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

January 10, 2003

Arnold Levine Named Professor At UMDNJ

February 28, 2003

NCI advisors complete terms on board, Appelbaum’s term as BSA chairman ends.

July 23, 2004

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999

Clinical Trials: For ER+ Breast Cancer, Post-Tamoxifen, NSABP Testing Aromasin In Large Trial

June 1, 2001